AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34475366 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder Stimulation Technique (BST)
Number of subjects: 124
Study 34475366 — intervention group
Group type: COMPARATOR
Intervention: Urethral Catheterization
Number of subjects: 124
Study 34475750 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) intravitreal implant 700 µg
Number of subjects: 700
Study 34475849 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34476122 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute medication overuse (AMO)
Number of subjects: 16789
Study 34476122 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple analgesics, combination analgesics, and opioids
Number of subjects: 16789
Study 34476122 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with AMO
Number of subjects: 16789
Study 34476122 — intervention group
Group type: EXPERIMENTAL
Intervention: AMO respondents
Number of subjects: 16789
Study 34476122 — intervention group
Group type: COMPARATOR
Intervention: AMO vs non-AMO migraine respondents
Number of subjects: 16789
Study 34476128 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone for 24 weeks (6 cycles)
Number of subjects: 200
Study 34476229 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) intervention, details on dosage and duration not available
Number of subjects: 0
Study 34476229 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 34476329 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-based comprehensive genomic profiling (PCR-CGP) test
Number of subjects: 32048
Study 34476329 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-CGP attempted
Number of subjects: 32048
Study 34476411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of effusion and haemarthrosis
Number of subjects: 150
Study 34476411 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovial fluid molecular protein response (MCP-1 and IL-6)
Number of subjects: 150
Study 34476411 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical predictors (baseline demographic and clinical factors)
Number of subjects: 150
Study 34476411 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee Injury and Osteoarthritis Outcome Score (KOOS)
Number of subjects: 150
Study 34476468 — intervention group
Group type: EXPERIMENTAL
Intervention: Omics model based on magnitude and timing of postprandial biomarkers
Number of subjects: 100
Study 34476468 — intervention group
Group type: EXPERIMENTAL
Intervention: Simpler model based on postprandial BP and age
Number of subjects: 100
Study 34476468 — intervention group
Group type: COMPARATOR
Intervention: Baseline clinical parameters or fasting biomarkers
Number of subjects: 100
Study 34476587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry electrode electroencephalography (EEG)
Number of subjects: 100
Study 34476587 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined weighted phase lag index and relative theta power
Number of subjects: 100
Study 34476621 — intervention group
Group type: EXPERIMENTAL
Intervention: Progranulin
Number of subjects: 541
Study 34476623 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-report measure of family therapy techniques (ITT-CEFT)
Number of subjects: 68
Study 34476665 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic stiffness measured by aortic pulse wave velocity (PWV)
Number of subjects: 408
Study 34476665 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and hypertension as predictors of aortic stiffness
Number of subjects: 408
Study 34476665 — intervention group
Group type: EXPERIMENTAL
Intervention: High aortic stiffness (PWV)
Number of subjects: 408
Study 34476728 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography performed within 7 days of stroke onset (n=91) and after 6 months (n=52)
Number of subjects: 99
Study 34476728 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent SDB (AHI ≥ 15 in both acute state and follow-up)
Number of subjects: 99
Study 34476728 — intervention group
Group type: EXPERIMENTAL
Intervention: AHI measurement
Number of subjects: 99
Study 34476771 — intervention group
Group type: EXPERIMENTAL
Intervention: ECL assay
Number of subjects: 0
Study 34476771 — intervention group
Group type: COMPARATOR
Intervention: Commercial ELISA kits (GenWay BioTech and Demeditec Diagnostics)
Number of subjects: 0
Study 34476771 — intervention group
Group type: COMPARATOR
Intervention: Commercial ELISA kits
Number of subjects: 0
Study 34477016 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 324
Study 34477016 — intervention group
Group type: COMPARATOR
Intervention: Control (no PRP)
Number of subjects: 324
Study 34477094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulance dispatched with lights and sirens
Number of subjects: 262
Study 34477094 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispatch criterion: sudden severe headache
Number of subjects: 262
Study 34477094 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from emergency call to neurosurgical admission
Number of subjects: 262
Study 34477094 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients brought directly to a hospital with neurosurgical facilities
Number of subjects: 262
Study 34477094 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dispatch criteria effectiveness
Number of subjects: 262
Study 34477094 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not initially brought to a hospital with neurosurgical facilities
Number of subjects: 262
Study 34477118 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 320
Study 34477845 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception leukocyte telomere length (measured as a ratio T/S using PCR)
Number of subjects: 1228
Study 34477937 — intervention group
Group type: EXPERIMENTAL
Intervention: fedratinib 600 mg
Number of subjects: 24
Study 34477937 — intervention group
Group type: COMPARATOR
Intervention: cocktail of digoxin 0.25 mg, rosuvastatin 10 mg, and metformin 1000 mg
Number of subjects: 24
Study 34477993 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (adalimumab, etanercept)
Number of subjects: 120
Study 34477993 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 120
Study 34477998 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA deficiency (n=35)
Number of subjects: 659
Study 34477998 — intervention group
Group type: COMPARATOR
Intervention: A-T patients without IgA deficiency (n=31)
Number of subjects: 659
Study 34477998 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival of patients with IgA deficiency
Number of subjects: 659
Study 34477998 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA as a surrogate marker
Number of subjects: 659
Study 34478115 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative neurostimulation
Number of subjects: 42
Study 34478460 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated cholera vaccine
Number of subjects: 12
Study 34478486 — intervention group
Group type: EXPERIMENTAL
Intervention: Akkermansia expansion in the gut
Number of subjects: 0
Study 34478486 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbial-derived indole compounds
Number of subjects: 0
Study 34478486 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum metabolome signatures
Number of subjects: 0
Study 34478487 — intervention group
Group type: EXPERIMENTAL
Intervention: Axi-cabtagene ciloleucel (axi-cel)
Number of subjects: 101
Study 34478487 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (SCHOLAR-1)
Number of subjects: 101
Study 34478498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-stored platelets (CSP)
Number of subjects: 0
Study 34478498 — intervention group
Group type: COMPARATOR
Intervention: Room temperature-stored platelets (RSP)
Number of subjects: 0
Study 34478737 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital single-operator cholangioscopy (DSOC) using the Mendoza Classification
Number of subjects: 14
Study 34478825 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding (TRF) - 4-6 hours eating window, 18-20 hours fasting window daily
Number of subjects: 32
Study 34478825 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding (TRF)
Number of subjects: 32
Study 34479230 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition transcranial burst electrostimulation device
Number of subjects: 0
Study 34479362 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-g glucose drink (OG)
Number of subjects: 10
Study 34479362 — intervention group
Group type: EXPERIMENTAL
Intervention: liquid mixed meal (LMM)
Number of subjects: 10
Study 34479517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (low carbohydrate diet)
Number of subjects: 57
Study 34479526 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-it intervention (health promotion intervention including a health pedagogic dialogue tool and a digital health app)
Number of subjects: 0
Study 34479581 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction SBRT (15-20 Gray)
Number of subjects: 40
Study 34479649 — intervention group
Group type: EXPERIMENTAL
Intervention: Arts-only intervention
Number of subjects: 120
Study 34479649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-only intervention
Number of subjects: 120
Study 34479649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based art intervention
Number of subjects: 120
Study 34479649 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 120
Study 34479654 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective writing by facilitators after each facilitation call
Number of subjects: 2
Study 34479654 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective writing process
Number of subjects: 2
Study 34479654 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of reflective writing
Number of subjects: 2
Study 34479739 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell therapy
Number of subjects: 267
Study 34479739 — intervention group
Group type: COMPARATOR
Intervention: Cone reconstruction (CR)
Number of subjects: 267
Study 34479925 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-BN-brachyury-TRICOM vaccine administered intravenously at three dose levels on days 1, 22, and 43.
Number of subjects: 13
Study 34479925 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-BN-brachyury-TRICOM vaccine
Number of subjects: 13
Study 34480095 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 42
Study 34480329 — intervention group
Group type: EXPERIMENTAL
Intervention: High contact perpetrators
Number of subjects: 4554
Study 34480329 — intervention group
Group type: EXPERIMENTAL
Intervention: Low contact perpetrators
Number of subjects: 4554
Study 34480329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual harassment perpetrators
Number of subjects: 4554
Study 34480329 — intervention group
Group type: COMPARATOR
Intervention: Non-perpetrators
Number of subjects: 4554
Study 34480368 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with carcinoembryonic antigen (CEA) and Her2/neu (Her2) peptides
Number of subjects: 0
Study 34480474 — intervention group
Group type: EXPERIMENTAL
Intervention: YuWell YE900 oscillometric blood pressure monitor
Number of subjects: 85
Study 34481135 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedure with added steps to conventional MIS radical hysterectomy
Number of subjects: 0
Study 34481605 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34482181 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin
Number of subjects: 37
Study 34482181 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 37
Study 34482353 — intervention group
Group type: EXPERIMENTAL
Intervention: Latency reversal agents (LRA) - HDAC inhibitor
Number of subjects: 13
Study 34482507 — intervention group
Group type: EXPERIMENTAL
Intervention: Global longitudinal strain (GLS) in sub-acute phase (-11.8 ± 3.0%)
Number of subjects: 77
Study 34482507 — intervention group
Group type: EXPERIMENTAL
Intervention: Global longitudinal strain (GLS) in chronic phase (-14.3 ± 2.9%)
Number of subjects: 77
Study 34482507 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of GLS from sub-acute to chronic phase
Number of subjects: 77
Study 34482636 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 0
Study 34482652 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life perceptions among frail older persons
Number of subjects: 78
Study 34482715 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk factors (alanine transaminase)
Number of subjects: 956
Study 34482715 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk factors (systolic blood pressure)
Number of subjects: 956
Study 34482715 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk factors (arterial hypertension)
Number of subjects: 956
Study 34482715 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk factors (non-high-density lipoprotein cholesterol)
Number of subjects: 956
Study 34482715 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk factors (low-density lipoprotein cholesterol)
Number of subjects: 956
Study 34483038 — intervention group
Group type: EXPERIMENTAL
Intervention: C3-targeted drug candidate
Number of subjects: 0
Study 34483270 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical insulin (1 unit per mL), applied 4 times per day until resolution of persistent epithelial defect (PED) or ulcer.
Number of subjects: 21
Study 34484101 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin-A treatment, dosage and duration not specified
Number of subjects: 0
Study 34484101 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34484187 — intervention group
Group type: EXPERIMENTAL
Intervention: iNeo-Vac-P01, a personalized neoantigen-based peptide vaccine
Number of subjects: 7
Study 34484431 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg orally each day continuously until unacceptable toxicity or tumor progression
Number of subjects: 22
Study 34484473 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab after concurrent chemoradiotherapy
Number of subjects: 0
Study 34484473 — intervention group
Group type: COMPARATOR
Intervention: Placebo after concurrent chemoradiotherapy
Number of subjects: 0
Study 34484473 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab with subsequent immunotherapy removed
Number of subjects: 0
Study 34484473 — intervention group
Group type: COMPARATOR
Intervention: Placebo with subsequent immunotherapy removed
Number of subjects: 0
Study 34484887 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy for Migraine (MBCT-M)
Number of subjects: 60
Study 34484887 — intervention group
Group type: COMPARATOR
Intervention: Wait list/treatment as usual (WL/TAU)
Number of subjects: 60
Study 34484928 — intervention group
Group type: EXPERIMENTAL
Intervention: eFIT (online moderated structured groups)
Number of subjects: 37
Study 34484928 — intervention group
Group type: EXPERIMENTAL
Intervention: eJournal (online independent journaling)
Number of subjects: 37
Study 34484928 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment-as-usual)
Number of subjects: 37
Study 34485200 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34485235 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare Non-Take-Up
Number of subjects: 0
Study 34485235 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34485595 — intervention group
Group type: EXPERIMENTAL
Intervention: filgrastim and plerixafor
Number of subjects: 11
Study 34485882 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional therapies (LRT) before liver transplantation (LT)
Number of subjects: 2441
Study 34485882 — intervention group
Group type: COMPARATOR
Intervention: All-comers group
Number of subjects: 2441
Study 34485882 — intervention group
Group type: EXPERIMENTAL
Intervention: UCSF-DS group
Number of subjects: 2441
Study 34486544 — intervention group
Group type: EXPERIMENTAL
Intervention: BChE-deficient neuroblastoma cells (KO)
Number of subjects: 0
Study 34486544 — intervention group
Group type: COMPARATOR
Intervention: Wild-type neuroblastoma cells (WT)
Number of subjects: 0
Study 34486544 — intervention group
Group type: EXPERIMENTAL
Intervention: KO xenografts in female mice
Number of subjects: 0
Study 34486544 — intervention group
Group type: COMPARATOR
Intervention: WT xenografts in female mice
Number of subjects: 0
Study 34486544 — intervention group
Group type: EXPERIMENTAL
Intervention: KO and WT tumors
Number of subjects: 0
Study 34487039 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD-XI score = 12
Number of subjects: 2993
Study 34487039 — intervention group
Group type: COMPARATOR
Intervention: MELD-XI score < 12
Number of subjects: 2993
Study 34487174 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 4104
Study 34487283 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal administered radioactivity
Number of subjects: 0
Study 34487786 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesion optical coherence tomography (OCT) imaging
Number of subjects: 100
Study 34487890 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted uterus retrieval
Number of subjects: 1
Study 34488636 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring Partner
Number of subjects: 9
Study 34488636 — intervention group
Group type: EXPERIMENTAL
Intervention: Worried Manager
Number of subjects: 9
Study 34488636 — intervention group
Group type: EXPERIMENTAL
Intervention: Desperate Overburdened
Number of subjects: 9
Study 34488662 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor with low dose dexamethasone
Number of subjects: 80
Study 34488832 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE4 allele presence
Number of subjects: 0
Study 34488884 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 9
Study 34489264 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative care management for diabetic patients
Number of subjects: 5000
Study 34489289 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breast feeding for at least 3 months
Number of subjects: 350
Study 34489309 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line treatment with RAS/BRAF mutation analysis
Number of subjects: 171
Study 34489309 — intervention group
Group type: COMPARATOR
Intervention: Patients with plasma RAS/BRAF clearance
Number of subjects: 171
Study 34489309 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who gained new RAS/BRAF mutations
Number of subjects: 171
Study 34489348 — intervention group
Group type: EXPERIMENTAL
Intervention: Community neurologists' experiences during the COVID-19 pandemic
Number of subjects: 20
Study 34489348 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of the COVID-19 pandemic on care provision
Number of subjects: 20
Study 34489348 — intervention group
Group type: EXPERIMENTAL
Intervention: Efforts to improve care delivery
Number of subjects: 20
Study 34489356 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high/high human development index country settings
Number of subjects: 1100
Study 34489356 — intervention group
Group type: COMPARATOR
Intervention: Medium/low human development index country settings
Number of subjects: 1100
Study 34489388 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid medications
Number of subjects: 248
Study 34489682 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum proBDNF
Number of subjects: 0
Study 34489682 — intervention group
Group type: COMPARATOR
Intervention: Mature BDNF
Number of subjects: 0
Study 34489850 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34490173 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management intervention
Number of subjects: 0
Study 34490414 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell depleting therapies (BCDTs)
Number of subjects: 11
Study 34490414 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 11
Study 34490424 — intervention group
Group type: EXPERIMENTAL
Intervention: Slip-perturbation training (St)
Number of subjects: 169
Study 34490424 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 169
Study 34490590 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype-guided strategy
Number of subjects: 1000
Study 34490590 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with ticagrelor or prasugrel
Number of subjects: 1000
Study 34490604 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restriction (2 g of sodium/day)
Number of subjects: 70
Study 34490604 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restriction (2 g of sodium/day) with sodium intake < 2500 mg/day
Number of subjects: 70
Study 34490604 — intervention group
Group type: COMPARATOR
Intervention: Control (3 g of sodium/day)
Number of subjects: 70
Study 34491103 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34491326 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary glycaemic load (GL)
Number of subjects: 103020
Study 34491326 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher contribution of medium/high-GI foods to energy intake
Number of subjects: 103020
Study 34491326 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher contribution of low-GI food/beverages to energy intake
Number of subjects: 103020
Study 34491406 — intervention group
Group type: EXPERIMENTAL
Intervention: OB (Optic neuritis) present
Number of subjects: 88
Study 34491406 — intervention group
Group type: EXPERIMENTAL
Intervention: Infratentorial lesions present
Number of subjects: 88
Study 34491406 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord lesions present
Number of subjects: 88
Study 34491406 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of two risk factors (OB, infratentorial or spinal cord lesions)
Number of subjects: 88
Study 34491406 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of three risk factors (OB, infratentorial and spinal cord lesions)
Number of subjects: 88